The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract

References

• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul;369(6499):77–81.
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020 Oct;586(7830):578–582.
   PubMed Web of Science ®Google Scholar
• Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 Aug;369(6505):806–811.
   PubMed Web of Science ®Google Scholar
• Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020 Aug;11(1):4081.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun;395(10240):1845–1854.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug;396(10249):479–488.
   PubMed Web of Science ®Google Scholar
• Gorbalenya AE, Enjuanes L, Ziebuhr J, et al. Nidovirales: evolving the largest RNA virus genome. Virus Res. 2006 Apr;117(1):17–37.
   PubMed Web of Science ®Google Scholar
• Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009 Jun;7(6):439–450.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Snijder EJ, Kikkert M, et al. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1–42.
   PubMed Web of Science ®Google Scholar
• Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020 Jun;368(6498):1499–1504.
   PubMed Web of Science ®Google Scholar
• Ye G, Wang X, Tong X, et al. Structural basis for inhibiting porcine epidemic diarrhea virus replication with the 3C-Like protease inhibitor GC376. Viruses. 2020 Feb;12(2):240.
   Web of Science ®Google Scholar
• Ma C, Sacco MD, Hurst B, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020 Aug;30(8):678–692.
   PubMed Web of Science ®Google Scholar
• Fu L, Ye F, Feng Y, et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020 Sep;11(1):4417.
   PubMed Web of Science ®Google Scholar
• Kim Y, Lovell S, Tiew KC, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol. 2012 Nov;86(21):11754–11762.
   PubMed Web of Science ®Google Scholar
• Tiew KC, He G, Aravapalli S, et al. Design, synthesis, and evaluation of inhibitors of norwalk virus 3C protease. Bioorg Med Chem Lett. 2011 Sep;21(18):5315–5319.
   Web of Science ®Google Scholar
• Vuong W, Khan MB, Fischer C, et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 2020 Aug;11(1):4282.
   PubMed Web of Science ®Google Scholar
• Kim Y, Mandadapu SR, Groutas WC, et al. Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease. Antiviral Res. 2013 Feb;97(2):161–168.
   PubMed Web of Science ®Google Scholar
• Mandadapu SR, Weerawarna PM, Gunnam MR, et al. Potent inhibition of norovirus 3CL protease by peptidyl α-ketoamides and α-ketoheterocycles. Bioorg Med Chem Lett. 2012 Jul;22(14):4820–4826.
   Web of Science ®Google Scholar
• Kim Y, Liu H, Galasiti Kankanamalage AC, et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog. 2016 Mar;12(3):e1005531.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018 Mar;9(2):e00221-18.
   PubMed Web of Science ®Google Scholar
• Cho A, Saunders OL, Butler T, et al. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett. 2012 Apr;22(8):2705–2707.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun;9(396):eaal3653.
   PubMed Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar;531(7594):381–385.
   PubMed Web of Science ®Google Scholar
• Yan VC, Muller FL. Advantages of the parent nucleoside GS-441524 over remdesivir for covid-19 treatment. ACS Med Chem Lett. 2020 Jul;11(7):1361–1366.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Wang J, Shuai L, Wang C, et al. Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein Cell. 2020 Oct;11(10):776–782.
   PubMed Web of Science ®Google Scholar
• Tempestilli M, Caputi P, Avataneo V, et al. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother. 2020 Oct;75(10):2977–2980.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan;11(1):222.
   PubMed Web of Science ®Google Scholar
• de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020 Mar;117(12):6771–6776.
   PubMed Web of Science ®Google Scholar
• Choy KT, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020 Jun;178:104786.
   PubMed Web of Science ®Google Scholar
• Murphy BG, Perron M, Murakami E, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol. 2018 Jun;219:226–233.
   PubMed Web of Science ®Google Scholar
• Shi Y, Li Y, Lei Y, et al. A dimerization-dependent mechanism drives the endoribonuclease function of Porcine Reproductive and Respiratory syndrome virus nsp11. J Virol. 2016 May;90(9):4579–4592.
   Web of Science ®Google Scholar
• Shi Y, Tong X, Ye G, et al. Structural characterization of the helicase nsp10 encoded by porcine reproductive and respiratory syndrome virus. J Virol. 2020 Jul;94(15):e02158-19.
   Web of Science ®Google Scholar
• Minor W, Cymborowski M, Otwinowski Z, et al. HKL-3000: the integration of data reduction and structure solution–from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr. 2006 Aug;62(Pt 8):859–866.
   PubMedGoogle Scholar
• Adams PD, Grosse-Kunstleve RW, Hung LW, et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948–1954.
   Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126–2132.
   PubMedGoogle Scholar
• Laskowski RA, Swindells MB. Ligplot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011 Oct;51(10):2778–2786.
   PubMed Web of Science ®Google Scholar
• Pedersen NC, Kim Y, Liu H, et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg. 2018 Apr;20(4):378–392.
   PubMed Web of Science ®Google Scholar
• Kim Y, Shivanna V, Narayanan S, et al. Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. J Virol. 2015 May;89(9):4942–4950.
   PubMed Web of Science ®Google Scholar
• Perera KD, Galasiti Kankanamalage AC, Rathnayake AD, et al. Protease inhibitors broadly effective against feline, ferret and mink coronaviruses. Antiviral Res. 2018 Dec;160:79–86.
   Web of Science ®Google Scholar
• Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 2020 Jul;32(3):107940.
   PubMed Web of Science ®Google Scholar
• Tchesnokov EP, Feng JY, Porter DP, et al. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019 Apr;11(4):326.
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020 May;295(20):6785–6797.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wu J, Wang H, et al. Structural Basis for RNA replication by the SARS-CoV-2 polymerase. Cell. 2020 Jul;182(2):417–428.e13.
   PubMed Web of Science ®Google Scholar
• Kokic G, Hillen HS, Tegunov D, et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun. 2021 Jan;12(1):279.
   PubMed Web of Science ®Google Scholar